OverviewSuggest Edit

The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world’s first and only medical device that can monitor and respond to brain activity.

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company’s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.

In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.

TypePrivate
Founded1999
HQMountain View, US
Websiteneuropace.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Mar 2019)142(+2%)

Key People/Management at NeuroPace

Frank Fischer

Frank Fischer

Chief Executive Officer, Board Member
Rebecca Kuhn

Rebecca Kuhn

Chief Financial Officer, Vice President, Finance & Administration
Martha Morrell

Martha Morrell

Chief Medical Officer
Isabella Abati

Isabella Abati

Vice President, Regulatory Affairs
Chi Nguyen

Chi Nguyen

Vice President, Marketing
Show more

NeuroPace Office Locations

NeuroPace has an office in Mountain View
Mountain View, US (HQ)
455 N Bernardo Ave
Show all (1)
Report incorrect company information

NeuroPace Financials and Metrics

Summary Metrics

Founding Date

1999

NeuroPace total Funding

$141 m

NeuroPace latest funding size

$74 m

Time since last funding

a year ago

NeuroPace investors

NeuroPace's latest funding round in October 2017 was reported to be $74 m. In total, NeuroPace has raised $141 m
View all funding rounds
Report incorrect company information

NeuroPace Online and Social Media Presence

Embed Graph
Report incorrect company information

NeuroPace News and Updates

NeuroPace raises $74 million to market seizure-monitoring device: Reuters

NeuroPace Inc said on Tuesday it raised $74 million in equity funding as the medical device maker looks to rapidly expand commercialization of its device to treat epileptic seizures.
Report incorrect company information

NeuroPace Blogs

27th Annual Epilepsy Awareness Stroll

Click Here to Register The post 27th Annual Epilepsy Awareness Stroll appeared first on NeuroPace, Inc.

Walk for Epilepsy – Boston

Click Here to Register The post Walk for Epilepsy – Boston appeared first on NeuroPace, Inc.

Eric’s Corner Support Group

Click Here to Register The post Eric’s Corner Support Group appeared first on NeuroPace, Inc.

Epilepsy Expo

Click Here to Register The post Epilepsy Expo appeared first on NeuroPace, Inc.

American Epilepsy Society Annual Meeting

Click Here to Register The post American Epilepsy Society Annual Meeting appeared first on NeuroPace, Inc.

Congress of Neurological Surgeons Annual Meeting

Click Here to Register The post Congress of Neurological Surgeons Annual Meeting appeared first on NeuroPace, Inc.
Show more

NeuroPace Frequently Asked Questions

  • When was NeuroPace founded?

    NeuroPace was founded in 1999.

  • Who are NeuroPace key executives?

    NeuroPace's key executives are Frank Fischer, Rebecca Kuhn and Martha Morrell.

  • How many employees does NeuroPace have?

    NeuroPace has 142 employees.

  • Who are NeuroPace competitors?

    Competitors of NeuroPace include DiaMedica Therapeutics, Intersect ENT and Sensome.

  • Where is NeuroPace headquarters?

    NeuroPace headquarters is located at 455 N Bernardo Ave, Mountain View.

  • Where are NeuroPace offices?

    NeuroPace has an office in Mountain View.

  • How many offices does NeuroPace have?

    NeuroPace has 1 office.